Non-Hematology Lab Insights — Apr 20, 2026

Source labs: KIMS Bill L029731026 (Apr 20, 2026). Method notes: ISE indirect (Na, K, Cl), PEPC (HCO3), Xylidyl blue (Mg).

Summary Table (Non-Hematology, Apr 20 2026)

Electrolyte Panel — Integrated Analysis

1. Sodium 128 — New Nadir, Moderate Hyponatremia

Trajectory: 138.8 (Jul 2025, baseline) → 136 (Jan 19) → 135→132 (late Jan–Mar) → 129 nadir (Mar 12) → 135 (Mar 30 transient) → 133 (Apr 13) → 128 (Apr 20)

This is a new absolute nadir, surpassing the previous low of 129 (Mar 12). The drop from 133→128 over 7 days is clinically significant. This is no longer mild hyponatremia (≥130) — it is moderate hyponatremia (125–129), which carries higher symptomatic risk in an 81-year-old.

The electrolyte pattern across 18 Na data points supports euvolemic hyponatremia / SIADH-type:
- Low Na, low Cl ✓
- Normal K (consistently 3.5–4.9 across 16 data points) ✓
- Normal HCO3 (consistently 22–28 across 15 data points) ✓
- Normal BUN 13.4, Cr 0.6 → low solute load, low urine osmolarity substrate ✓

The concurrent worsening Mg 1.2 is likely a contributing factor: hypomagnesemia impairs renal tubular sodium handling and potentiates ADH-excess states.

Vaptans remain contraindicated (posaconazole CYP3A4 interaction — see Vaptan Assessment). Primary management remains fluid restriction + salt loading + Mg correction.

2. Chloride 93 — Persistent Hypochloremia

Cl has been below 98 for nearly all readings since Jan 2026. The Apr 20 value of 93 mmol/L is at the lower end of the observed range (93–96 since Feb 2026). This tracks directly with Na — confirming dilutional/SIADH-type rather than primary Cl loss.

3. Bicarbonate 22.8 — Low-Normal, HCO3 Drop

HCO3 dropped from 27.2 (Apr 13) to 22.8 (Apr 20), the lowest recorded value. Still within normal range (22–29) but this is the widest week-over-week swing observed (−4.4 mmol/L). Worth monitoring — a sustained fall below 22 would indicate metabolic acidosis.

The low-normal HCO3 combined with low Na and low Cl raises the question of a concurrent mild metabolic acidosis, but the current values remain technically normal.

4. Potassium 4.7 — Reassuringly Normal

Despite severe electrolyte disturbance in Na/Cl/Mg, potassium has remained robustly normal throughout 16 data points (3.5–4.9 mmol/L). This is both clinically reassuring and diagnostically useful — preserved K with low Na is the hallmark SIADH electrolyte pattern. No K wasting from Mg depletion has manifested yet (Mg-K relationship can cause hypokalemia at severe depletion levels).

Magnesium 1.2 — Progressive Hypomagnesemia, Escalating Priority

Trajectory: 1.4 mg/dL (Mar 2) → 1.2 mg/dL (Apr 20) | Ref: 1.60–2.60

At 1.2 mg/dL (73% of lower reference limit), this is moderate hypomagnesemia (not yet severe, which is <0.5 mmol/L or ~1.2 mg/dL on the molar scale — essentially at the severe threshold by some definitions).

Clinical implications for this patient:
- Hyponatremia: Mg depletion impairs ADH regulation, worsening SIADH tendency. The concurrent Na 128 nadir and Mg 1.2 nadir on the same date is likely not coincidental.
- Cardiac arrhythmia: In an 81-year-old, Mg 1.2 significantly elevates risk of AF, QT prolongation, and ventricular ectopy. No ECG data in the vault.
- Neuromuscular: Muscle cramps, weakness, tremor — all contributors to fall risk (already elevated for age, anemia, chemo).
- Potassium stability: Currently K 4.7 (normal), but Mg depletion can cause refractory hypokalemia — this requires monitoring.
- Chemo relationship: Azacitidine and venetoclax can both cause renal Mg wasting. If this is renal wasting (vs GI), oral supplementation will be partially ineffective; IV Mg may be needed.

Dietary interventions previously assessed (ellu/sesame ~351 mg/100g, ragi puttu ~137 mg/100g, muringa ila ~86–150 mg/100g — see Magnesium Diet Kerala Context). At 1.2 mg/dL, dietary alone is likely insufficient. Oral Mg glycinate 200–400 mg/day or IV magnesium sulfate should be discussed with Dr. Bijay.

Renal Function — Stable

Creatinine 0.6 mg/dL (Apr 6, most recent): Stable at lower end of KIMS reference (0.60–1.20). All 5 data points range 0.6–0.9 — no AKI, no nephrotoxicity from Aza/Ven/posaconazole/acyclovir regimen. For an 81-year-old female with reduced muscle mass, a Cr of 0.6 likely represents normal to slightly reduced GFR (estimated eGFR by CKD-EPI: ~75–85 mL/min/1.73m²; muscle mass adjustment may apply).

BUN 13.4 mg/dL (Apr 6): Normal. Low BUN relative to creatinine (BUN:Cr ratio ~22:1 using mg/dL equivalents) suggests adequate hydration but also low protein intake / low solute load — relevant to SIADH pathophysiology (low solute intake limits ability to excrete free water). Supports the dietary recommendation to increase protein.

No Cr data point for Apr 20 — renal function was not re-checked on the latest panel.

Liver Function — Continued Hepatic Preservation

Latest full LFT (2026-04-06): TBil 0.2, ALT 11, AST 15, ALP 63, TP 7.3, Alb 4.4 — all normal.

Three serial panels (Jan 19, Mar 2, Apr 6) — all entirely normal. Despite 4+ months of triple potentially hepatotoxic therapy (azacitidine + venetoclax + posaconazole):
- Transaminases stable and low (ALT 14→11→11, AST 19→16→15) — trend is actually declining
- ALP 77→60→63 — no cholestatic pattern
- Albumin 4.4 (stable) — good synthetic function and nutritional reserve
- No LFT drawn on Apr 20 panel; last LFT is 14 days old

The normal albumin (4.4 g/dL) also rules out protein-losing states or hepatic synthetic failure as contributors to the hyponatremia.

HbA1c 5.7% — Apparently Improved T2DM, Interpretive Caution

Trajectory: 6.7% (Jul 2025) → 6.8% (Nov 2025, frank DM) → 5.7% (Mar 2026, pre-DM boundary)

A 1.1% drop in HbA1c while on chemotherapy is striking. Three possible explanations:
1. True glycemic improvement — dietary modification, reduced oral intake, weight loss
2. Artifactually low due to increased RBC turnover — AML + treatment causes high red cell turnover (transfusions, hemolysis, erythropoietic suppression/recovery). HbA1c reflects avg glucose over ~90-day RBC lifespan; shorter RBC lifespan → falsely lower HbA1c
3. Combination of both

Given the documented macrocytosis (MCV 90–99), active AML, 4+ transfusions (Hb nadir 6.8 → recovery to 11.4), HbA1c should be interpreted with caution. Fasting glucose or continuous glucose monitoring would provide more reliable glycemic data. See Counter Intuitive Insights for the "HbA1c illusion" analysis.

Key Gaps on Latest Panel (Apr 20)

1. No LFT on Apr 20 — last LFT 14 days old (Apr 6). Should be checked at same frequency as electrolytes.
2. No Creatinine on Apr 20 — especially relevant now that Na is 128; eGFR needed to exclude renal contribution to hyponatremia.
3. No urine osmolality / urine sodium — SIADH remains unconfirmed. Spot urine Na and osmolality would confirm/exclude.
4. No ECG — Mg 1.2 in elderly patient warrants QTc check.
5. No Calcium on Apr 20 — previously transient hypercalcemia (Jan 19, 10.7); last Ca 9.9 (Mar 2). Should be tracked alongside Mg.
6. Phosphorus never measured — electrolyte panel is incomplete without phosphate (relevant in malnourished/chemo patients for refeeding risk).

Integrated Interpretation

The Apr 20 non-hematology labs reveal a worsening, interlocked electrolyte disturbance centered on hypomagnesemia as a likely amplifier of SIADH-type hyponatremia:

Azacitidine/Venetoclax
    ↓
Renal Mg wasting (likely)
    ↓
Mg 1.2 → impaired ADH regulation + impaired Na tubular handling
    ↓
Worsening SIADH → Na 128 (new nadir)
    ↓
↓ Na → ↓ Cl (dilutional) + ↓ HCO3 (low-normal)
    ↓
K preserved (euvolemic pattern — not K-wasting nephropathy)

Renal and hepatic function remain intact — the electrolyte disturbance is not organ-failure-driven. Correction priority: Mg first (IV if renal wasting suspected), then fluid restriction + salt loading for Na.

Related Pages

• Sodium — 18 data points, new nadir 128
• Magnesium — worsening 1.4 → 1.2
• Chloride — persistent hypochloremia
• Bicarbonate — low-normal, monitoring warranted
• Potassium — stable (reassuring)
• Lft — normal × 3 panels
• Creatinine — stable renal function
• Hba1C — improved but interpret with caution
• Hyponatremia — condition page
• Vaptan Assessment — vaptans contraindicated
• Siadh Diet Indian Context — dietary management
• Magnesium Diet Kerala Context — Mg dietary sources
• Counter Intuitive Insights — HbA1c illusion